B · Normal
[Novartis Rhapsido® (remibrutinib) is approved by the FDA and becomes the first drug to treat symptomatic dermatomes] On October 7, Novartis announced that its oral highly selective Bruton tyrosine kinase inhibitor Rhapsido® (remibrutinib) has been approved by the US FDA for the treatment of symptomatic dermatomes (SD) in adults whose symptoms cannot be adequately controlled by H1 antihistamines. This is a new indication for the drug after chronic spontaneous urticaria (CSU).
biopharmaceutical 🕐 2026-10-07 23:53
#biopharmaceutical
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On October 10, the U.S. Food and Drug Administration (FDA) approved a drug for t 10-10 00:50 [The Hang Seng Index and Hang Seng Technology Index both rose by about 1%, and p 10-06 16:09 On October 3, biopharmaceutical company Agenus reported that its BOT+BAL combina 10-03 22:54 [Preparations for the 2026 APEC Business Leaders Summit are progressing smoothly 09-29 11:24 [Nanexa and Novo Nordisk reach a 1.165 billion euro global licensing and coopera 09-25 13:33 [Two departments: Pilot project for electronic customs clearance of imported dru 09-21 11:28

Comments

0/500
Captcha (click to refresh)
No comments yet